Bioanalytical Services
Anti-drug antibody testing for clinical development
Crux Biolabs provides anti-drug antibody (ADA) testing services to support immunogenicity assessment for biologics in clinical research. Our scientists develop, qualify and validate fit-for-purpose assays to identify and characterise immune responses that may affect therapeutic exposure, safety or activity.
Using established ligand binding assay (LBA) platforms and tailored assay approaches, we generate reliable data to support informed clinical-development decisions.
ADA testing for immunogenicity assessment
Crux Biolabs provides tiered ADA testing tailored to the therapeutic, mechanism of action, study design and required endpoints. Our approach supports the detection, confirmation and characterisation of treatment-emergent anti-drug antibodies in clinical-study samples.
Our services may include screening, confirmatory testing and titration to identify ADA-positive samples, confirm specificity and characterise the relative magnitude of the antibody response. Where scientifically appropriate, we also develop neutralising-antibody assays to assess whether detected ADAs may inhibit a therapeutic’s biological activity.
Designed around your study
| Study consideration | How Crux approaches it |
|---|---|
| Therapeutic and mechanism | Define an immunogenicity testing approach appropriate for the biologic, molecular target and mechanism of action |
| Study phase and objectives | Align assay scope and performance with the clinical protocol, intended use and required endpoints |
| Tiered testing pathway | Determine screening, confirmation, titration and neutralising-antibody requirements, where applicable |
| Drug and target interference | Assess drug, target and matrix interference, and apply fit-for-purpose mitigation measures |
| Method lifecycle | Support feasibility, assay development, cut-point establishment, qualification and validation, clinical sample analysis and reporting |
Applications in clinical research
Anti-drug antibody testing supports the assessment of unwanted immune responses to biologic therapeutics. Crux Biolabs can support:
ADA screening and confirmation
Detecting and confirming treatment-emergent anti-drug antibodies, with domain-specific confirmation approaches for complex biologics, including bispecific and trispecific molecules.
ADA titration
Characterising the relative magnitude of an antibody response
Neutralising-antibody assessment
Evaluating whether ADAs may inhibit therapeutic activity, where appropriate
Drug- and target-tolerant assays
Addressing relevant drug, soluble-target and matrix interference
Immunogenicity data integration
Supporting interpretation alongside pharmacokinetic, pharmacodynamic, safety and clinical data
Quality and compliance
Crux Biolabs’ ADA testing services are delivered within a quality framework aligned with applicable regulatory expectations for clinical immunogenicity assessment. We apply fit-for-purpose assay development, qualification and validation approaches based on the intended use of each method and relevant immunogenicity guidance from regulatory authorities, including the FDA where applicable.
Crux Biolabs operates an ISO/IEC 17025-accredited, GCLP-compliant quality management system. Controlled processes, documented procedures and data-review practices support reliable, traceable and scientifically defensible results for clinical research.
Addressing immunogenicity assay challenges
ADA assay performance can be affected by circulating therapeutic drug, soluble target, pre-existing antibodies and matrix-related interference. Crux Biolabs evaluates these factors early in assay development to identify potential risks and select an appropriate fit-for-purpose approach.
Our scientists work with sponsors to address technical challenges through assay format selection, critical-reagent selection, sample-handling considerations and, where appropriate, drug- or target-tolerance approaches. This helps maintain meaningful ADA detection and interpretation throughout clinical development.
Scientific support throughout the immunogenicity lifecycle
Our scientists work directly with sponsors from initial immunogenicity planning through to clinical sample analysis and data delivery. This collaborative approach supports timely technical decisions, practical troubleshooting and clear communication throughout the project.
We provide guidance on assay design, critical reagents, sample handling, cut-point determination, validation planning and data review, helping keep the immunogenicity approach aligned with the study objectives as the program progresses.
Connected bioanalytical services
ADA data are most useful when considered alongside related bioanalytical endpoints. Crux Biolabs can support integrated clinical bioanalysis through:
